Newlin Investment Company

SpIntellx has the first-mover advantage in Precision Pathology and Spatially Intelligent Biology by applying truly unbiased spatial analytics software powered by explainable AI to decipher the complex cancer biology. SpIntellx’s software solutions have the potential to unlock a plethora of new applications in medicine and research by answering the fundamental question “Why?”, thus revealing the underlying patient-specific disease network biology, across each stage of the drug development, diagnostics, and treatment pipelines.

C2Sense is currently working to bring two products to market: Halo Diagnostics, a digitally connected immunoassay reader with a user-friendly hardware and software, provide near-PCR sensitivity to address the gap in the patient-to-provider workflow. The Halo hardware is supported by a cloud-based, HIPAA compliant software solution that provides real-time test results to patients using an app (iOS/Android) or a web portal and, simultaneously, can be shared with a Telehealth physician to expedite time sensitive therapeutic prescriptions. To rapidly scale this technology, C2Sense partners with with immunoassay test manufacturers that own large portfolios of antigen tests that, pre-pandemic, had been exclusively providing tests to hospitals and urgent care facilities. By pairing these tests with a digitally enabled, highly sensitive test readers, remote physicians have access to store and review the same test results their patients are seeing in real time. In conjunction with Halo, C2Sense has designed different sensing solutions to provide product quality information and counterfeit detection from the point of manufacturing out to the customer. Discretely printed onto or included in a product, the tags are safe, versatile molecular additives that instantaneously report valuable information about the status of a good. They identify counterfeits and, where required, they are designed to react to problems encountered in the distribution chain (temperature change, oxygen sensing, and more). The tags are compatible with products as small as a pill, or can coat entire packaging surfaces, enabled by the tags’ compatibility with a myriad of printing and coating techniques.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Sharp Edge Labs, Inc. engages in developing biosensors for cellular biology research and high-throughput screening. The company’s products include targeted biosensors to the cellular biology research community. It offers its products based on the fluorogenic activating proteins that provide a detection method for cellular changes, which is amendable to high-throughput screening and follow-up. The company was incorporated in 2011 and is based in Pittsburgh, Pennsylvania.

Machine Translation answers the need of today’s global business for high volume and high velocity content localization and enterprise translation. Safaba provides Enterprise Machine Translation solutions to the world’s leading global enterprises.

Liquid X is an electronic company that enables users to print metal traces and films that deliver results comparable to the bulk metal. The company partners with manufacturers within the electronics industry to develop and print functional components utilized in various devices, including sensors; heating elements; smart textiles, and many others. Liquid X inks are unique because, unlike other metallic conductive inks, their products contain actual metal atoms, not nanoparticles or metal flakes. The processing parameters of Liquid X metallic inks are attractive due to the low conversion temperatures and short processing times. The resulting films or traces exhibit desirable characteristics such as high conductivity, thin and precise features, and excellent adhesion. An advantage of the low temperature processing is the ability to use of a wide range of substrates from fibrous materials such as paper and gauze to flexible, organic material such as plastics. In addition, low viscosity provides the opportunity for the use of a variety of deposition methods such as inkjet, slot die, flexography, offset, and gravure.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Plextronics specializes in printed electronics. The company's focus is on organic light emitting diode (OLED) displays and lighting, specifically conductive inks and associated process technologies. Plextronic's technology will enable the mass production of these printed devices and therefore lower the cost.